Plasmodium vivax malaria is a mosquito-borne infection that typically causes cycles of fever with chills, headache, body aches, and fatigue; some people also feel nausea or notice an enlarged spleen on exam. Illness can start weeks after a mosquito bite, but P. vivax can “sleep” in the liver and return months or even years later without another bite, leading to relapses if not fully treated. Most cases occur in Asia, the Pacific, the Middle East, and the Americas, but travelers and people visiting family in these regions can bring it back to non‑endemic countries. While P. vivax malaria is often less severe than falciparum malaria, it can still cause serious illness, especially in children, pregnant people, and those with other health conditions; deaths are less common but do occur. Treatment usually includes medicines to clear parasites in the blood and a second drug to eliminate dormant liver forms to prevent relapse, alongside supportive care like fluids and fever control.
How many people live with Plasmodium vivax malaria?
Worldwide, the World Health Organization estimated about 249 million malaria cases in 2022; Plasmodium vivax may account for roughly 3%–5% of these, suggesting about 7–12 million people had P. vivax malaria that year (an estimate, not a direct count). In the United States, the CDC reported about 2,000 malaria cases in 2021; P. vivax typically makes up about 10%–15% of U.S. cases, suggesting roughly 200–300 people with P. vivax malaria that year.
Overview
Plasmodium vivax malariaSymptoms
Plasmodium vivax malaria often begins with early symptoms of fever, chills, headache, and feeling tired. Many develop sweating, body aches, nausea, or vomiting, with fevers that may spike every 48 hours. Some notice pale skin or mild yellowing from anemia.
Outlook and prognosis
Most people with Plasmodium vivax malaria recover with prompt treatment, but tiredness and weakness can linger for weeks. Relapses are common without a liver‑stage medicine, so prevention of recurrence is key. Severe illness is less frequent than with falciparum malaria.
Causes and risk factors
Caused by Plasmodium vivax spread by Anopheles mosquitoes; rarely via transfusion or mother‑to‑baby. Risk rises with travel or residence in endemic areas, dusk‑to‑dawn exposure, poor protection, pregnancy, and no prior immunity. Duffy‑positive blood groups are more susceptible.
Genetic influences
Genetics matters for Plasmodium vivax malaria. Variations in Duffy antigen (DARC) can reduce risk of infection; many people of West African ancestry are protected. Other genes, like G6PD variants, influence drug safety and how severe illness can become.
Diagnosis
Doctors diagnose Plasmodium vivax malaria using travel/exposure history and fever patterns, then confirm with blood tests. A microscope smear identifies parasites and species; rapid tests or PCR may assist. If results are negative, repeat smears over 24–48 hours.
Treatment and drugs
Plasmodium vivax malaria is managed with fast-acting medicines to clear the blood-stage infection and lower fever, often using artemisinin-based combinations or chloroquine where still effective. To prevent relapse, doctors add primaquine or tafenoquine to target dormant liver forms. Care also includes treating anemia, monitoring for recurrence, preventing mosquito bites, and tailoring medicines for pregnancy, G6PD status, and local resistance.
Symptoms
Plasmodium vivax malaria often begins like a bad flu, with fever, chills, and feeling unwell. Early symptoms of Plasmodium vivax malaria can mimic common viral illnesses, which makes it easy to miss in the first days after travel or exposure. Symptoms vary from person to person and can change over time. Many have fevers that come back in cycles every other day, along with fatigue and body aches.
Fevers can come in waves, often every 48 hours (about 2 days). Temperature may spike high, then drop with drenching sweats. This pattern is common in Plasmodium vivax malaria.
Intense shivering can be followed by heavy sweating as the fever breaks. Blankets may not help during the chill phase. Clothes can feel soaked afterward.
A deep, throbbing headache is common. Light and noise may feel harder to tolerate.
Muscle and joint aches can feel like a strong flu. Climbing stairs or carrying groceries may feel unusually hard.
How people usually first notice Plasmodium vivax malaria?
Many people first notice Plasmodium vivax malaria after returning from travel to a tropical or subtropical area when a sudden fever hits, often with chills, headache, and body aches that feel like a bad flu. A telling pattern is fever spikes that come and go every 48 hours, though early on the timing can be irregular; some also notice nausea, fatigue, or sweating, and a few develop an enlarged spleen that a doctor can feel on exam. Because P. vivax can “sleep” in the liver and relapse weeks to months later, the first signs of Plasmodium vivax malaria may appear long after leaving an endemic region, so any unexplained fever after travel should prompt medical testing.
Types of Plasmodium vivax malaria
Plasmodium vivax malaria has a few well-recognized patterns that affect how symptoms start, how often fevers return, and the risk of recurrence. The parasite can hide in the liver and wake up months later, which drives many of the differences people notice. When reading about the types of Plasmodium vivax, you’ll often see them grouped by where the parasite strain circulates and how it behaves over time. Not everyone will experience every type.
Chesson type
Fevers and chills start sooner after the mosquito bite and relapse more quickly. People may have repeated bouts a few weeks apart, often with higher parasite levels. This pattern is common in parts of Southeast Asia and Oceania.
St. Elizabeth type
Illness appears after a moderate delay, and relapses are spaced out over months. Symptoms may be milder between episodes but can still disrupt sleep and daily activities. This pattern has been described in the Americas.
North Korean type
The first attack may come late, sometimes many months after travel or exposure. Relapses tend to be widely spaced, which can make diagnosis harder if exposure was long ago. Fatigue and intermittent fevers can linger.
Madagascar type
Onset and relapses are intermediate in timing compared with faster and slower variants. People may notice a return of fevers after a period of feeling well. This type reflects regional parasite behavior rather than differences in patient factors.
Temperate strain pattern
In cooler climates, the initial illness often occurs long after exposure, sometimes 6–12 months later. Relapses are fewer but can still occur after seasons change. This helps explain types of Plasmodium vivax that appear long after travel.
Tropical strain pattern
In warmer regions, illness tends to start sooner and relapse more frequently. Fevers may recur every few weeks without full recovery unless liver-stage treatment is given. Night sweats, headaches, and tiredness often track with these relapses.
Can I slow down the onset of symptoms?
There isn’t a proven way to slow the first symptoms once Plasmodium vivax malaria is in the body; they usually start within weeks, though this parasite can sometimes lie quiet in the liver and cause illness months later. You can lower your chance of getting sick by preventing infection: sleep under insecticide-treated bed nets, use repellent, wear long sleeves and pants, and, if you’re traveling to a risk area, take the malaria prevention tablets recommended by travel-health guidelines. After a P. vivax diagnosis, doctors may add a medicine that clears sleeping liver forms to reduce later episodes; these steps reduce risk but don’t guarantee prevention, and getting advice early can help you choose the safest plan.
What genetics can tell you about symptoms
Certain Duffy-negative blood group variants make people less likely to get P. vivax malaria because the parasite struggles to enter red blood cells. In those who do get infected, genetic traits like G6PD deficiency can increase risk of anemia, jaundice, and hemolysis.
Causes and risk factors
Plasmodium vivax malaria is caused by the P. vivax parasite spread through the bite of an infected Anopheles mosquito, and its dormant liver forms can reactivate months later if they aren’t cleared with specific medicines. Doctors distinguish between risk factors you can change and those you can’t. Risk factors for Plasmodium vivax malaria include living in or traveling to parts of South and Southeast Asia, the Western Pacific, and Latin America where Anopheles mosquitoes are common, warm rainy seasons, and housing near standing water. Being outdoors from dusk to dawn, sleeping without bed nets or window screens, and not using insect repellent or protective clothing raise exposure. Biologic and genetic factors also matter: little or no prior immunity (young children and travelers), pregnancy, and weaker immune defenses increase risk, while a blood type common in parts of Africa (Duffy‑negative) provides protection, meaning most others are more susceptible where exposure occurs.
What are the most common causes or risk factors?
Plasmodium vivax malaria is caused by a parasite spread through the bite of infected mosquitoes that carry malaria, so the biggest risks are living in or traveling to areas where it’s common, not using bed nets or repellent, missing or stopping prevention medicines, and spending evenings outdoors; people with little prior exposure (young children, travelers) and pregnant people face higher risk. A past P. vivax infection can also flare again because dormant parasites can hide in the liver, while a common West and Central African blood type that lacks the Duffy marker makes infection much less likely.
Environmental and biological risk factors
Plasmodium vivax malaria develops when infected Anopheles mosquitoes transmit the parasite to humans. Risk reflects your surroundings and your body’s state, from local mosquito patterns to conditions like pregnancy or a weak immune system. Doctors often group risks into internal (biological) and external (environmental). Below are key environmental risk factors for Plasmodium vivax malaria and the biological features that can raise susceptibility or recurrence.
Living or spending time in regions where Plasmodium vivax malaria circulates raises exposure risk. Transmission is common in parts of South Asia, Southeast Asia, Oceania, Latin America, and some areas of Africa. Risk can vary within countries by altitude and season.
Wet seasons and warm temperatures boost mosquito numbers and parasite development. Plasmodium vivax can complete its life cycle in cooler climates than some other malaria types, extending risk to higher altitudes and temperate zones. Peaks often follow heavy rains.
Puddles, rice fields, irrigation canals, and slow-moving water create breeding sites for Anopheles mosquitoes. Living close to these habitats increases the chance of bites. Land-use changes or construction can temporarily raise local risk.
Mosquito activity often peaks around dusk and dawn. This concentrates exposure during these hours. Overcast, humid evenings can further increase biting.
Genetic risk factors
Genetic differences influence who becomes infected, how often malaria returns, and how well certain medicines work. The parasite’s own genes also shape its ability to invade red blood cells and to resist treatment. This overview highlights genetic risk factors for Plasmodium vivax malaria that are well established in clinical research. Some risk factors are inherited through our genes.
Duffy-positive blood: Having the Duffy protein on red blood cells makes it easier for the parasite to enter. People with Duffy-positive blood have higher susceptibility to infection. This protein is common in many populations.
Duffy-null variant: People who inherit the Duffy-null trait lack this red-cell protein and are strongly protected from P. vivax infection. Protection is high but not absolute because rare parasite variants can bypass this pathway.
Parasite entry changes: Some P. vivax strains carry genetic changes in the proteins they use to attach to and enter young red blood cells. These changes may allow infection even when Duffy is absent or weakly expressed. This can expand risk in areas where many people were previously shielded.
Relapse-prone strains: Genetic differences between parasite lineages affect how often and how soon dormant liver stages wake up. This raises the chance of recurrent Plasmodium vivax malaria after an initial recovery. Strains from some regions relapse more frequently than others.
Drug resistance genes: Mutations in the parasite can reduce the effect of chloroquine and related medicines. When this happens, clearing the blood-stage infection is harder and illness can last or return. Resistance patterns vary by region.
CYP2D6 variants: Changes in a liver enzyme gene can make primaquine less active in the body. People with poor-metabolizer variants face a higher risk of recurrent Plasmodium vivax malaria after standard dosing.
Lifestyle risk factors
Planning a trip, sleeping with windows open on a warm night, or spending evenings outdoors can change your chances of mosquito bites—and with them, your risk of Plasmodium vivax malaria. Here we focus on lifestyle risk factors for Plasmodium vivax malaria, especially for travelers and people in areas where it circulates. If risks concern you, a simple conversation with your doctor is a good compass.
Traveling to regions where Plasmodium vivax malaria is common without prevention steps raises risk. Seeing a travel clinic and following country-specific guidance can lower your chances of infection.
Spending time outside at dusk or dawn increases exposure to night-biting mosquitoes. Shifting activities indoors or choosing well-protected spaces during these times can help.
Sleeping without an insecticide-treated net leaves you exposed overnight when bites are more likely. Using a properly tucked, treated net can reduce Plasmodium vivax malaria transmission while you sleep.
Not using or reapplying an effective mosquito repellent lowers your protection. Applying repellent correctly to skin and clothing creates a barrier against bites.
Risk prevention
Plasmodium vivax malaria is spread by mosquito bites, so prevention focuses on avoiding bites, using protective tools, and taking medicines when appropriate. Prevention is about lowering risk, not eliminating it completely. Knowing the early symptoms of Plasmodium vivax malaria—fever, chills, sweats, headache—and getting tested quickly can protect your health and limit spread.
Apply an EPA-registered repellent with DEET, picaridin, IR3535, or oil of lemon eucalyptus on exposed skin. Reapply as directed, especially after sweating or swimming.
Use a long-lasting insecticide-treated bed net every night. Tuck it under the mattress and repair any holes.
Choose long sleeves, long trousers, and socks in the evening and at night. Treat clothing and gear with permethrin as labeled.
Keep windows and doors screened, and use fans or air-conditioning when available. Where offered, consider indoor residual spraying by trained teams.
Can you prevent Plasmodium vivax malaria?
Plasmodium vivax malaria can’t be fully prevented, but you can greatly lower your risk by preventing mosquito bites and, when advised for travel to risk areas, taking preventive antimalarial medicine. Helpful steps include sleeping under treated bed nets, using mosquito repellent, wearing long sleeves and treated clothing, and staying in well‑screened or air‑conditioned rooms; community mosquito control also reduces exposure. If you’ve already had P. vivax, medicines that clear lingering liver forms can cut the chance of relapse, and there’s no widely available vaccine yet.
Transmission
Plasmodium vivax malaria is spread mainly through the bite of an infected Anopheles mosquito, which picks up the parasite from someone with malaria and passes it to the next person it bites. It does not spread through everyday contact, coughing, sex, food, or water, and people with Plasmodium vivax malaria are not directly contagious to others; only mosquitoes can carry it from person to person. Rarely, it can be passed through blood (such as a transfusion, organ transplant, or shared needles) or from a pregnant parent to the baby before or during birth. Because P. vivax can rest quietly in the liver and cause relapses months later, someone may become a source for mosquito transmission again if bitten during a relapse. In practical terms, how contagious is Plasmodium vivax malaria depends on whether Anopheles mosquitoes that can carry malaria are present—without them, spread in a community is very unlikely.
When to test your genes
Plasmodium vivax malaria is an acquired infection, so most people don’t need genetic testing. Consider testing if you’ve had severe reactions to antimalarials (for drug-metabolism genes like G6PD or CYP variants) or have G6PD deficiency risk, as results can guide safe medications and prevent hemolysis during treatment or primaquine radical cure.
Diagnosis
When fever, chills, and fatigue come in waves—especially after travel or living in a malaria area—doctors think about malaria and start testing right away. Early and accurate diagnosis can help you plan ahead with confidence. If you’re wondering how Plasmodium vivax malaria is diagnosed, it typically involves a blood smear to look for the parasite and tests to confirm the exact species. Because symptoms can mimic flu or other infections, clinicians often check for other causes at the same time.
Doctors review recent or past travel to malaria regions and mosquito exposure. They also ask about prior malaria and preventive medicines. Relapses months after travel can point toward Plasmodium vivax.
Clinicians document fever patterns, chills, headache, and fatigue. On exam, they may find fever, pallor from anemia, or an enlarged spleen.
A drop of blood is examined under a microscope to detect malaria parasites and identify the species. This is the standard test and also estimates how many red cells are infected. If the first smear is negative but suspicion remains high, repeat smears are done over 24–48 hours.
Finger‑stick tests can detect malaria proteins within minutes when microscopy isn’t immediately available. They help flag infection but may be less sensitive at low levels, so confirmation with a blood smear is often needed.
How is Plasmodium vivax malaria diagnosed?
Doctors diagnose Plasmodium vivax malaria by confirming parasites in a blood sample—most often by looking at a drop of blood under a microscope to see the parasite and tell the type of malaria, sometimes with a rapid test when a microscope isn’t available, and in some centers with advanced lab tests if results are unclear. Your symptoms and recent travel to areas where malaria is common guide testing, but a lab test is needed to confirm the diagnosis and to choose the right treatment.
Stages of Plasmodium vivax malaria
Plasmodium vivax malaria tends to unfold in phases tied to how the parasite moves through the body, and not everyone experiences each step the same way. Symptoms often begin after a quiet period, then come in cycles of fever and chills, with possible relapses months later. Different tests may be suggested to help confirm Plasmodium vivax malaria and rule out other causes of fever.
Silent liver phase
After an infected mosquito bite, parasites travel to the liver and multiply without causing symptoms. This stage usually lasts 1–2 weeks but can be longer.
Uncomplicated blood phase
Parasites enter red blood cells and trigger fevers, chills, headaches, and fatigue. Early symptoms of Plasmodium vivax malaria can feel like the flu and may start suddenly.
Fever cycle (paroxysms)
Attacks often follow a pattern—shivering and feeling very cold, then high fever, then heavy sweating as it breaks. In P. vivax, these waves commonly repeat about every 48 hours.
Dormant liver forms
Some parasites "sleep" in the liver and can wake months or even years later. These relapses can bring back Plasmodium vivax malaria even after the first illness clears.
Severe illness risk
A small number of people develop complications like anemia or breathing problems and need urgent care. Severe P. vivax malaria is less common than with P. falciparum but can occur.
Recovery and relapse prevention
With the right medicines, fevers settle and parasites clear from the blood. A second medicine may be used to clear dormant liver forms and lower the chance of relapse.
Outlook and prognosis
Looking at the long-term picture can be helpful. For most people with Plasmodium vivax malaria, the illness responds well to the right medicines, and survival is very high compared with more severe forms like falciparum malaria. Still, relapses are common because P. vivax can hide in the liver as “sleeping” forms that wake weeks or months later, causing fevers to return. This is why treatment often has two parts: one to clear the active infection in the blood and another to target the liver stage to prevent relapse.
The outlook is not the same for everyone, but people with timely diagnosis and full treatment usually recover fully between episodes and return to normal routines. Risks rise if care is delayed, if medicines aren’t completed, or if there’s anemia, pregnancy, very young age, or other illnesses. Severe complications are uncommon but can happen, including significant anemia and, rarely, organ problems; deaths from Plasmodium vivax malaria are rare in settings with access to care. Early symptoms of Plasmodium vivax malaria—fever, chills, headache, and fatigue—can mimic the flu, so getting tested after travel or exposure is important.
Over time, most people experience fewer relapses once the liver stage is eradicated with the appropriate medication, assuming they’re a safe candidate for it. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle, including whether someone has G6PD deficiency, which affects which anti-relapse drugs are safe to use. With ongoing care, many people maintain full day-to-day function between episodes and avoid further attacks once the liver stage is treated. Talk with your doctor about what your personal outlook might look like, including relapse risk, safe anti-relapse options, and steps to take if a fever returns.
Long-term effects
For many, the fever and chills settle after treatment, but some effects can linger or return and affect daily routines. Long-term effects vary widely, and they don’t look the same for everyone. Even when early symptoms of Plasmodium vivax malaria fade, the parasite’s dormant form in the liver can trigger setbacks weeks or months later. Most people recover fully over time, but repeat illness can drain energy and blood levels.
Plasmodium vivax malaria can come back in waves because dormant liver forms can wake up later. These relapses may happen weeks to months after the first illness and can repeat several times. Each episode can bring fever, chills, and fatigue again.
Repeated infections can lower red blood cell levels over time. This can cause tiredness, shortness of breath, and pale skin. Anemia often improves when relapses stop.
The spleen may stay bigger than usual for weeks to months after Plasmodium vivax malaria. This can cause a sense of fullness or pain under the left ribs. Rarely, a very enlarged spleen can rupture.
Some people feel worn down for weeks after the main illness ends. Energy can return slowly, especially if relapses occur. Daily tasks may feel harder until strength rebuilds.
How is it to live with Plasmodium vivax malaria?
Living with Plasmodium vivax malaria often means feeling mostly well between attacks, then suddenly facing waves of fever, chills, headache, and exhaustion that can derail work, school, caregiving, and sleep for days. Because P. vivax can “hide” in the liver and relapse weeks to months later, many spend time anticipating the next episode, arranging quick access to care, and staying vigilant about medications that clear both the blood-stage infection and the dormant liver forms. Family members and coworkers may need to adjust plans or share responsibilities during relapses, and they can help by supporting mosquito-bite prevention at home—using bed nets, screens, and repellents—and encouraging follow-through with treatment and follow-up testing. For many, practical routines—hydration, rest, prompt fever checks, and prevention during travel or rainy seasons—restore a sense of control and reduce the ripple effects on daily life.
Treatment and drugs
Plasmodium vivax malaria is treated to clear the parasite from the blood, prevent relapses from dormant liver forms, and manage symptoms like fever and chills. Treatment often starts with a fast-acting antimalarial—commonly artemisinin-based combination therapy (ACT) or chloroquine in regions where the parasite is still sensitive—to stop the acute illness. To prevent the infection from coming back, doctors add a second medicine that targets the liver “sleeper” stage, usually primaquine or tafenoquine, after testing for G6PD deficiency to reduce the risk of dangerous anemia. Supportive care can make a real difference in how you feel day to day, including fluids, fever reducers like acetaminophen or ibuprofen, and monitoring for complications such as anemia or low blood sugar. Pregnant people, children, and those with other health conditions may need tailored regimens, so ask your doctor about the best starting point for you.
Can you cure Plasmodium vivax malaria?
Yes—Plasmodium vivax malaria is usually curable with prescription medicines that clear the parasite from the blood, plus another medicine to get rid of forms that can hide in the liver so it doesn’t come back. Some people need a quick blood test first to be sure the anti‑relapse pills are safe for their red blood cells, and the exact drug choice can vary by where you were infected. With prompt treatment, most people feel better quickly and treatment lowers the chance of relapse and complications.
Non-drug treatment
Living with Plasmodium vivax malaria can leave you wiped out with waves of fever, chills, and sweats, so day-to-day care matters. Alongside medicines, non-drug therapies can keep you safer, more comfortable, and help limit spread to others. These steps support recovery, protect those around you from mosquito bites, and help you notice when symptoms are changing. Seek urgent medical care if symptoms worsen or you develop confusion, trouble breathing, severe weakness, or repeated vomiting.
Drink plenty of fluids—water, oral rehydration solution, broths—to replace sweat losses and prevent dehydration. Rest in a cool, quiet room to reduce strain on your body. Take small, frequent sips if nausea is present.
Use light clothing, a fan, and lukewarm sponging or cool compresses to make high fevers more tolerable. Keep the room well ventilated but avoid chills. Check temperature regularly so you can track changes.
Eat small, easy-to-digest meals and snacks to maintain energy when appetite is low. Include protein and salty fluids to replace losses from sweating. A bedtime snack may help if you’re prone to low blood sugar.
Keep a simple log of fevers, chills, sweats, and fatigue to spot patterns or relapses. Noting early symptoms of Plasmodium vivax malaria—like headache, body aches, and feeling feverish—can help you seek timely care. Bring your records to appointments so your team sees the full picture.
Your genes may have an impact on how drugs work for you
Genes can change how your body handles antimalarial drugs—some people break medicines down too quickly, too slowly, or activate them poorly, which shifts effectiveness and side‑effect risk. For example, G6PD variants raise hemolysis risk with primaquine or tafenoquine, and CYP2D6 variants can blunt primaquine response.
Pharmacological treatments
Treatment for Plasmodium vivax malaria targets two stages: the active infection in the blood and the dormant forms in the liver that can cause relapses. Even when early symptoms of Plasmodium vivax malaria are mild, doctors usually treat promptly to prevent complications and future relapses. Consider asking if genetic testing for G6PD deficiency is recommended before medicines like primaquine or tafenoquine, because these drugs are only safe when G6PD levels are adequate. Choices vary by region and drug resistance patterns, so your care team will tailor the plan to where the infection was acquired and your health needs.
Used in regions where P. vivax remains chloroquine-sensitive to clear parasites from the blood. It eases fever and chills quickly but does not prevent relapse on its own. Resistance is common in many areas, so local guidance matters.
Preferred where chloroquine resistance is present to treat the blood-stage infection. It is taken by mouth over several doses and is generally well tolerated. A separate anti-relapse medicine is still needed to clear dormant liver forms.
An alternative ACT used for chloroquine-resistant P. vivax. The longer-acting partner drug can help suppress parasites after the artemisinin component. As with other ACTs, add an anti-relapse drug to prevent recurrence.
A 14‑day course targets dormant liver forms (hypnozoites) to prevent relapse. Safe use requires normal G6PD activity, confirmed by testing, to avoid red-blood-cell breakdown. It is avoided during pregnancy and in breastfeeding if the infant’s G6PD status is unknown.
Genetic influences
Your genes can shape how likely you are to get Plasmodium vivax malaria and how you respond to treatment. A change in a gene (mutation or variant) can sometimes affect health. People who are born without a specific protein on their red blood cells—often called the Duffy protein—are largely protected from Plasmodium vivax malaria; this genetic resistance to Plasmodium vivax malaria helps explain why the infection is less common in parts of West and Central Africa, though rare infections can still occur. Another inherited trait, G6PD deficiency, doesn’t change your chance of catching P. vivax, but it makes anti-relapse medicines such as primaquine and tafenoquine unsafe without prior testing because they can trigger breakdown of red blood cells. Differences in a liver-enzyme gene can also make primaquine less effective, increasing the risk of relapse if the dormant liver forms aren’t cleared. Genes are only part of the story; sharing your family history and asking about G6PD testing can help your care team plan safe, effective treatment for Plasmodium vivax malaria.
Is Plasmodium vivax malaria genetic?
Genetics matters for Plasmodium vivax malaria. Variations in Duffy antigen (DARC) can reduce risk of infection; many people of West African ancestry are protected. Other genes, like G6PD variants, influence drug safety and how severe illness can become.
Having a genetic risk is not necessarily a diagnosis
Genetic variants are a normal part of being human and are widespread in the population. Most variants do not directly affect health and simply reflect usual human differences. For many genes, having a variant linked to a condition suggests a possible connection rather than a certain diagnosis, especially when several genes and environmental factors are involved. However, in some situations a single well-studied variant in a specific gene can be enough to confirm a diagnosis.
Pharmacogenetics—how genetics influence drug effects
Treatment for Plasmodium vivax malaria often has two parts—clearing parasites in the blood and then preventing relapse from dormant liver forms—and your genetics can affect both safety and success. Before prescribing primaquine or tafenoquine for the liver stage, doctors check for glucose-6-phosphate dehydrogenase (G6PD) deficiency, an inherited enzyme difference that can trigger dangerous breakdown of red blood cells with these drugs. Differences in a gene involved in drug metabolism (CYP2D6) can also reduce how well your body activates primaquine, which may raise the risk of relapse even when you take the full course. Genetic testing can sometimes identify how your body will handle these medicines, helping your care team choose a safe and effective plan. Tafenoquine appears less affected by CYP2D6 than primaquine, but it carries the same G6PD-related safety risk and still requires testing beforehand. Other factors—such as drug interactions, liver health, and local parasite resistance—also guide treatment, so genetics is one part of a bigger decision.
Interactions with other conditions
When Plasmodium vivax malaria occurs alongside another health issue, tiredness can feel more intense and recovery may take longer. Doctors call it a “comorbidity” when two conditions occur together. Plasmodium vivax malaria often worsens anemia and, during pregnancy, it raises the chances of maternal anemia and low birth weight, so extra monitoring is important. In people with G6PD deficiency, the medicines used to clear dormant liver forms (to prevent relapses) can trigger red blood cell breakdown, so testing for G6PD before primaquine or tafenoquine is a key safety step. HIV or tuberculosis can further weaken the body’s defenses, and overlapping infections like dengue or bacterial illnesses may cause similar fevers, making it harder to sort out early symptoms of Plasmodium vivax malaria. Because of these links, clinicians usually check for coinfections and tailor treatment plans—especially in pregnancy and when G6PD deficiency is possible—to reduce complications and prevent relapse.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
What other conditions can cause similar symptoms to Plasmodium vivax malaria?
Other illnesses that can look similar include other types of malaria (especially falciparum malaria) and viral infections such as dengue fever, influenza (flu), COVID-19, and chikungunya. Bacterial and other infections like typhoid fever, pneumonia, and a tick-borne illness called babesiosis (seen in some parts of the U.S. and Europe) can also cause fever, chills, sweats, headache, and tiredness like vivax malaria.
History
Throughout history, people have described fever illnesses that came and went with the seasons, often near wetlands or after travel. In ships’ logs and village notes, patterns emerged: chills at dusk, sweats by night, and days of seeming recovery before the cycle returned. Families and communities once noticed patterns of relapses weeks or months after someone seemed well, a clue that pointed to Plasmodium vivax malaria long before the parasite was seen under a microscope.
Ancient physicians in Greece, South Asia, and China wrote about intermittent fevers and enlarged spleens, linking sickness to marshy air. Not every early description was complete, yet together they built the foundation of today’s knowledge. The turning point came in the late 1800s when researchers identified malaria parasites in human blood and showed that Anopheles mosquitoes carried them. Soon after, scientists recognized different malaria species; P. vivax stood out because people could fall ill again without a new mosquito bite.
From early theories to modern research, the story of P. vivax malaria has been shaped by its relapsing nature. In the 20th century, doctors learned that dormant forms can “sleep” in the liver and wake later, causing new bouts. This explained why some soldiers and travelers became sick long after leaving tropical regions. It also pushed public health efforts to think beyond bed nets and treatment of bloodstream infection, toward medicines that target the hidden liver stage.
With each decade, mapping improved. P. vivax malaria was found across Asia, the Pacific, parts of the Middle East, and the Americas, including temperate zones where winters paused transmission. Communities at higher altitudes or with cooler climates often faced fewer cases, but the relapse feature meant the burden persisted even when mosquito numbers dropped. In parallel, genetic studies revealed why some populations had lower risk: people who lack the Duffy antigen on red blood cells are relatively protected, a finding that helped explain regional differences in infection rates.
In recent decades, awareness has grown that P. vivax malaria is not always “benign.” Severe illness can occur, especially with repeated infections, anemia, or in pregnancy. Safer liver-stage treatments expanded options, but required screening for an enzyme deficiency (G6PD) to avoid side effects, reflecting how advances often bring new layers of careful practice. Today, elimination programs focus on both preventing mosquito bites and clearing dormant parasites, guided by surveillance that tracks relapses, resistance patterns, and migration. Looking back helps explain why controlling P. vivax malaria demands persistence: the parasite’s ability to hide and return has shaped its history—and continues to shape how clinicians and communities work to prevent, diagnose, and treat it.